{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Optune",
    "query": {
      "intervention": "Optune"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 41,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Optune&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T10:29:38.713Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01894061",
      "title": "NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NovoTTF-l00A",
          "type": "DEVICE"
        },
        {
          "name": "Quality of Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-09-18",
      "completion_date": "2019-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio • Cleveland, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894061"
    },
    {
      "nct_id": "NCT02348255",
      "title": "NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Brain Glioblastoma",
        "Recurrent Adult Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Electric Field Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-01",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2018-01-09",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Atlanta, Georgia",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02348255"
    },
    {
      "nct_id": "NCT06556563",
      "title": "EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Optune® device",
          "type": "DEVICE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "NovoCure GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 741,
      "start_date": "2025-02-03",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06556563"
    },
    {
      "nct_id": "NCT03223103",
      "title": "Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Poly-ICLC",
          "type": "DRUG"
        },
        {
          "name": "Tumor Treating Fields",
          "type": "DEVICE"
        },
        {
          "name": "Peptides",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "BIOLOGICAL"
      ],
      "sponsor": "Adilia Hormigo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2018-03-01",
      "completion_date": "2029-05-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03223103"
    },
    {
      "nct_id": "NCT03194971",
      "title": "NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Tumor samples from patients treated with TTFields at initial diagnosis.",
          "type": "OTHER"
        },
        {
          "name": "Tumor samples from patients treated with TTFields at tumor recurrence.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-06-01",
      "completion_date": "2023-06-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03194971"
    },
    {
      "nct_id": "NCT04396860",
      "title": "Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Gliosarcoma",
        "MGMT-Unmethylated Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Contrast-enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NovoTTF-100A Device",
          "type": "DEVICE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DEVICE",
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2020-09-01",
      "completion_date": "2025-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 285,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Auburn",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04396860"
    },
    {
      "nct_id": "NCT04757662",
      "title": "Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Grade III Astrocytoma",
        "Grade IV Astrocytoma",
        "Astrocytoma, Grade IV",
        "Astrocytoma, Grade III"
      ],
      "interventions": [
        {
          "name": "Tadalafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2021-05-14",
      "completion_date": "2023-06-07",
      "has_results": false,
      "last_update_posted_date": "2023-06-13",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04757662"
    },
    {
      "nct_id": "NCT00379470",
      "title": "Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "NovoTTF-100A",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NovoCure Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 236,
      "start_date": "2006-09",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2012-05-01",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 15,
      "location_summary": "Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00379470"
    },
    {
      "nct_id": "NCT03477110",
      "title": "Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "NovoTTF-200A Device",
          "type": "DEVICE"
        },
        {
          "name": "Tumor Treating Fields Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-05-04",
      "completion_date": "2024-01-26",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03477110"
    },
    {
      "nct_id": "NCT01954576",
      "title": "NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioblastoma",
        "Brain Neoplasms"
      ],
      "interventions": [
        {
          "name": "NovoTTF-100A",
          "type": "DEVICE"
        },
        {
          "name": "Quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory biomarker analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE",
        "GENETIC"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2013-10-10",
      "completion_date": "2021-05-14",
      "has_results": false,
      "last_update_posted_date": "2022-10-31",
      "last_synced_at": "2026-09-02T10:29:38.713Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • St Louis, Missouri",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01954576"
    }
  ]
}